Abstract:Since the discovery of rapamycin, considerable progress has been made in unraveling the details of the mammalian target of rapamycin (mTOR) signaling network, including the upstream mechanisms that modulate mTOR signaling functions, and the roles of mTOR in the regulation of mRNA translation and other cell growth-related responses. mTOR is found in two different complexes within the cell, mTORC1 and mTORC2, but only mTORC1 is sensitive to inhibition by rapamycin. mTORC1 is a master controller of protein synthesis, integrating signals from growth factors within the context of the energy and nutritional conditions of the cell. Activated mTORC1 regulates protein synthesis by directly phosphorylating 4E-binding protein 1 (4E-BP1) and p70S6K (S6K), translation initiation factors that are important to cap-dependent mRNA translation, which increases the level of many proteins that are needed for cell cycle progression, proliferation, angiogenesis, and survival pathways. In normal physiology, the roles of mTOR in both glucose and lipid catabolism underscore the importance of the mTOR pathway in the production of metabolic energy in quantities sufficient to fuel cell growth and mitotic cell division. Several oncogenes and tumor-suppressor genes that activate mTORC1, often through the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, are frequently dysregulated in cancer. Novel analogs of rapamycin (temsirolimus, everolimus, and deforolimus), which have improved pharmaceutical properties, were designed for oncology indications. Clinical trials of these analogs have already validated the importance of mTOR inhibition as a novel treatment strategy for several malignancies. Inhibition of mTOR now represents an attractive anti-tumor target, either alone or in combination with strategies to target other pathways that may overcome resistance. The far-reaching downstream consequences of mTOR inhibition make defining the critical molecular effector mechanisms that mediate the anti-tumor response and associated biomarkers that predict responsiveness to mTOR inhibitors a challenge and priority for the field.

Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression

Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast

TOR controls translation initiation and early G1 progression in yeast

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast

Amino Acid Regulation of TOR Complex 1.

Phosphoproteome Profiling Revealed The Importance Of Mtor Inhibition On Cdk1 Activation To Further Regulate Cell Cycle Progression

Rapamycin induces the G0 program of transcriptional repression in yeast by interfering with the TOR signaling pathway

Target of Rapamycin (TOR) Regulates Growth in Response to Nutritional Signals

The histone H2B Arg95 residue links the pheromone response pathway to rapamycin-induced G1 arrest in yeast

Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.

Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins

TOR2 plays the central role in rapamycin-induced lifespan extension in budding yeast

Regulatory Function of Phosphorylation and Ubiquitination on The TORC1 Signaling Pathway

TORC2 signaling is antagonized by protein phosphatase 2A and the Far complex in Saccharomyces cerevisiae

Targeting mTOR globally in cancer: thinking beyond rapamycin.

Regulation of cellular growth by the Drosophila target of rapamycin dTOR

The Mammalian Target of Rapamycin Complex 2 Controls Folding and Stability of Akt and Protein Kinase C

The Role of GSK3β in Rapamycin-Mediated Cell Cycle Regulation

Trypanosome TOR complex 2 functions in cytokinesis